Business Wire

ADELAÏDE-GROUP

11.4.2023 10:15:43 CEST | Business Wire | Press release

Share
The Adelaïde Group announces sustained turnover growth of over 9% in 2022

The Adelaide group, which includes Verlingue, Génération and Cocoon, has achieved €338 million in turnover in 2022, up 9.3%. These results are in line with its ambition of achieving a turnover of more than €400m by the end of the IMPACT 2024 Plan.

“In a consolidating industry, being a family-owned broker with a long-term vision allows us to pursue a strong growth, combining sustainability and profitability. We are proud of these results, which highlight the dedication of our teams,” states Jacques Verlingue, Chairman of the Adelaïde Group.

Specialising in corporate protection, Verlingue achieved a turnover of €239m this year, up 8.6%, of which 6% was organic growth. The broker also pursued its external growth with two acquisitions, Depeyre in France and RT Global Insurance in Portugal.

Génération, which specialises in the management of healthcare and personal protection benefits, is stepping up its momentum with a 13.8% growth rate (€86m in turnover).

Lastly, Cocoon, which specialises in the digital distribution of healthcare insurance products to private individuals, confirms its ambition with a stable turnover of €14m in 2022.

“2022 confirms that the Adelaide Group's growth is buoyant and controlled, in line with the 2024 strategic plan, with the aim of offering our customers even more added value,” says Gilles Bénéplanc, CEO of the Adelaïde Group.

Adelaïde reaffirms its ambition is to become a leading broker in Europe through its family-owned and independent model

The Adelaïde Group is implementing this European ambition through strong organic growth and acquisitions. Verlingue is consolidating its international position with an international turnover share of 29%. After five acquisitions in five years (Switzerland, France, United Kingdom, Portugal), Verlingue wishes to accelerate this trend in new geographical areas and new businesses.

“These results reflect the group's commitment to its European strategy. We have the ambition to continue to build on this momentum through new acquisitions in new countries as opportunities arise,” explains Benjamin Verlingue, Deputy CEO of the Adelaïde Group.

Controlled change in governance and ambitious recruitment

The excellent results for 2022 also support the business plan of the group, which is celebrating its 90th anniversary this year.

In 2024, the group's governance will evolve as Benjamin Verlingue will take over from Jacques Verlingue as Chairman. This handover is part of the continuity and the desire to preserve the group's spirit. Benjamin Verlingue will continue to step up the diversification and geographical expansion of the group’s operations.

In this context, the Adelaïde Group announces the appointment of Anne-Jacques de Dinechin as CEO of Verlingue. He will manage Verlingue with the aim of continuing to achieve profitable growth in each of its business segments.

Currently employing 2,200 people, Adelaïde aims to recruit 300 people by 2023.

About Adelaïde

The Adelaïde Group specialises in insurance consultancy, intermediation, distribution and management, with the aim of enabling its clients to run their businesses through effective risk management by helping them protect their operations and employees. Over the past 90 years, the Group has been tirelessly innovating, growing and reinventing itself to become one of the main players in insurance brokerage in France, with three successful companies to date: Verlingue, Génération and Cocoon. Organic growth, strategic acquisitions and international expansion and digital transformation are the four priorities that the Group has set itself to achieve its objective of building a large, family-owned and independent insurance brokerage group with a European dimension.
2,200 employees
€2,600 m in premiums negotiated
2.2 million policy holders (health and life insurance)
27 offices in France and Europe (the UK, Switzerland and Portugal)
www.adelaidegroup.fr

(*): growth based on proforma 2021 turnover

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230405005671/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye